ConductScience.org, home

Paper23040887

Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.

Roufosse FE and 14 others. J Allergy Clin Immunol, 2013. Cited by 146 papers, by iCite.

Cite this record

ConductScience Library. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. Papers, record 23040887. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23040887

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
PubMed
Journal
J Allergy Clin Immunol
PubMed
Year
2013
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
146
iCite
Relative citation ratio, by iCite
4.83
iCite
Revised in PubMed
2025-05-29
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Roufosse FEFlorence E
2Kahn JEJean-Emmanuel
3Gleich GJGerald J
4Schwartz LBLawrence B
5Singh ADAnish D
6Rosenwasser LJLanny J
7Denburg JAJudah A
8Ring JJohannes
9Rothenberg MEMarc E
10Sheikh JJaved
11Haig AEAnn E
12Mallett SAStephen A
13Templeton DNDeborah N
14Ortega HGHector G
15Klion ADAmy D

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Hypereosinophilic SyndromeMajor topic
Adolescent
Adrenal Cortex Hormones
Adult
Aged
Double-Blind Method
Eosinophilia
Female
Humans
Male
Middle Aged
Time
Young Adult

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
ZIA AI001130Intramural NIH HHSUnited StatesZIAAI001130PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116487232Orphan drug development is progressing too slowly.Br J Clin Pharmacol2006https://conductscience.org/library/papers/16487232PubMed
218344568Treatment of patients with the hypereosinophilic syndrome with mepolizumab.N Engl J Med2008https://conductscience.org/library/papers/18344568PubMed
321501869Hemophagocytic syndrome associated NK/T nasal type lymphoma presenting as hypereosinophilic syndrome: a case report and literature review.Leuk Res2011https://conductscience.org/library/papers/21501869PubMed
417868856Lymphocytic variant hypereosinophilic syndromes.Immunol Allergy Clin North Am2007https://conductscience.org/library/papers/17868856PubMed
519264687Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.N Engl J Med2009https://conductscience.org/library/papers/19264687PubMed
620810155Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.J Allergy Clin Immunol2010https://conductscience.org/library/papers/20810155PubMed
711799357Asthma therapies and Churg-Strauss syndrome.J Allergy Clin Immunol2002https://conductscience.org/library/papers/11799357PubMed
822460074Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.J Allergy Clin Immunol2012https://conductscience.org/library/papers/22460074PubMed
919264686Mepolizumab and exacerbations of refractory eosinophilic asthma.N Engl J Med2009https://conductscience.org/library/papers/19264686PubMed
1019910029Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.J Allergy Clin Immunol2009https://conductscience.org/library/papers/19910029PubMed
1117128345Rare essentials: drugs for rare diseases as essential medicines.Bull World Health Organ2006https://conductscience.org/library/papers/17128345PubMed
1221958585Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.J Allergy Clin Immunol2011https://conductscience.org/library/papers/21958585PubMed
1310511609Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.N Engl J Med1999https://conductscience.org/library/papers/10511609PubMed

Download CSV of references

Cited by78

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 146 citations.

PMIDTitleJournalYearIn PapersSource
42367766Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.Front Immunol2026https://conductscience.org/library/papers/42367766PubMed
42095000Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES.J Allergy Clin Immunol Glob2026https://conductscience.org/library/papers/42095000PubMed
41322417Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence.Front Immunol2025https://conductscience.org/library/papers/41322417PubMed
40943043Paradoxical Use of Benralizumab in Reactive Hypereosinophilia from Toxocariasis and Tuberculosis Co-Infection-Case Report and Literature Review.Int J Mol Sci2025https://conductscience.org/library/papers/40943043PubMed
40486501Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes.Front Allergy2025https://conductscience.org/library/papers/40486501PubMed
40296395Improving patient outcomes: Mepolizumab's impact in IL-5-mediated diseases.Lung India2025https://conductscience.org/library/papers/40296395PubMed
40120806Long-Term Efficacy and Safety of Benralizumab Treatment for PDGFRA-Negative Hypereosinophilic Syndrome.J Allergy Clin Immunol Pract2025https://conductscience.org/library/papers/40120806PubMed
39666063Effectiveness and safety of intravenous immunoglobulin for peripheral neuropathy in EGPA patients: a retrospective study.J Neurol2024https://conductscience.org/library/papers/39666063PubMed
39574910Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database.Front Med (Lausanne)2024https://conductscience.org/library/papers/39574910PubMed
39389908Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.Br J Haematol2024https://conductscience.org/library/papers/39389908PubMed
39389714Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis.Immunol Allergy Clin North Am2024https://conductscience.org/library/papers/39389714PubMed
39234416Effect of benralizumab on inflammation in skin after intradermal allergen challenge in patients with moderate-to-severe atopic dermatitis.J Allergy Clin Immunol Glob2024https://conductscience.org/library/papers/39234416PubMed
38966441Hypereosinophilia and Left Ventricular Thrombus: A Case Report and Literature Review.Cureus2024https://conductscience.org/library/papers/38966441PubMed
37886027GEMA 5.3. Spanish Guideline on the Management of Asthma.Open Respir Arch2023https://conductscience.org/library/papers/37886027PubMed
37648281Idiopathic hypereosinophilic syndrome presenting as cardiac tamponade and multiorgan dysfunction.BMJ Case Rep2023https://conductscience.org/library/papers/37648281PubMed
37419574HES and EGPA: Two Sides of the Same Coin.Mayo Clin Proc2023https://conductscience.org/library/papers/37419574PubMed
37266434Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach.Front Immunol2023https://conductscience.org/library/papers/37266434PubMed
37259416Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37259416PubMed
37122022French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.Orphanet J Rare Dis2023https://conductscience.org/library/papers/37122022PubMed
37064032Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome.Front Med (Lausanne)2023https://conductscience.org/library/papers/37064032PubMed

See all 78 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
FIP1L181608PubTator's text mininghttps://conductscience.org/library/genes/81608NCBI Gene
GGT12678PubTator's text mininghttps://conductscience.org/library/genes/2678NCBI Gene
IL53567PubTator's text mininghttps://conductscience.org/library/genes/3567NCBI Gene
PDGFRA5156PubTator's text mininghttps://conductscience.org/library/genes/5156NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23040887

GET https://conductscience.org/api/papers/v1/23040887/cited_by?page=2